Novel vaccine approaches for protection against intracellular pathogens

Current Opinion in Immunology

Volumn 28, Issue 1, 2014, Pages 58-63

  Griffiths, Kristin L ^a   Khader, Shabaana A ^a  

^a Department of Molecular Microbiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CORD FACTOR; DNA VACCINE; GLYCOSYLPHOSPHATIDYLINOSITOL; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LIPOSOME; LIVE VACCINE; MEMBRANE PROTEIN; MONOPHOSPHOLIPID A; MYCOBACTERIUM TUBERCULOSIS VACCINE; MYCOBACTERIUM VACCINE; PLASMID DNA; PROTEIN DNAK; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINE; VECTORED VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL KILLING; CELL SURFACE; CELLULAR IMMUNITY; DNA VECTOR; HUMAN; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; NONHUMAN; PHENOTYPE; REVIEW; VACCINATION;

ANIMALS; GENETIC VECTORS; HUMANS; INTRACELLULAR SPACE; T-LYMPHOCYTES; VACCINES;

EID: 84895747776     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.02.003     Document Type: Review

References (52)

1. Conlan J.W. Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol 2011, 6:391-405.
2. Igietseme J.U., Eko F.O., Black C.M. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines 2011, 10:1585-1596.
3. Pitt J.M., Blankley S., McShane H., O'Garra A. Vaccination against tuberculosis: how can we better BCG?. Microb Pathog 2013, 58:2-16.
4. Singh B., Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine 2012, 30:3834-3842.
5. Torrado E., Fountain J.J., Robinson R.T., Martino C.A., Pearl J.E., Rangel-Moreno J., Tighe M., Dunn R., Cooper A.M. Differential and site-specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse. PLoS ONE 2013, 8:e61681.
6. + T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol 2009, 16:444-452.
7. Gopal R., Rangel-Moreno J., Slight S., Lin Y., Nawar H.F., Fallert Junecko B.A., Reinhart T.A., Kolls J., Randall T.D., Connell T.D., et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol 2013, 6:972-984.
8. Griffiths K.L., Stylianou E., Poyntz H.C., Betts G.J., Fletcher H.A., McShane H. Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice. PLoS ONE 2013, 8:e78312.
9. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., Shen F., Eaton S.M., Gaffen S.L., Swain S.L., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
10. Cruz A., Fraga A.G., Fountain J.J., Rangel-Moreno J., Torrado E., Saraiva M., Pereira D.R., Randall T.D., Pedrosa J., Cooper A.M., et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010, 207:1609-1616.
11. Gopal R., Rangel-Moreno J., Junecko B.A., Mallon D., Chen K., Pociask D., Connell T.D., Reinhart T.A., Alcorn J.F., Ross T.M. Short communication: mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology following influenza infection. Am J Pathol 2014, 84(1):55-63. (in press).
12. Graham F.L., Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995, 3:207-220.
13. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., Colloca S., Cortese R., Hill A.V. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010, 78:145-153.
14. Zhu J., Huang X., Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007, 81:3170-3180.
15. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999, 6:1574-1583.
16. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., Siani L., Naddeo M., Grazioli F., Esposito M.L., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4(115):ra112.
17. Dicks M.D., Spencer A.J., Edwards N.J., Wadell G., Bojang K., Gilbert S.C., Hill A.V., Cottingham M.G. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 2012, 7:54038.
18. Hoft D.F., Blazevic A., Stanley J., Landry B., Sizemore D., Kpamegan E., Gearhart J., Scott A., Kik S., Pau M.G., et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012, 30:2098-2108.
19. Smaill F., Jeyanathan M., Smieja M., Medina M.F., Thanthrige-Don N., Zganiacz A., Yin C., Heriazon A., Damjanovic D., Puri L., et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013, 5:205ra134.
20. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., Fletcher H.A., Hill AV: 1. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
21. Delaloye J., Roger T., Steiner-Tardivel Q.G., Le Roy D., Knaup Reymond M., Akira S., Petrilli V., Gomez C.E., Perdiguero B., Tschopp J., et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009, 5:480-1000.
22. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., Shea J.E., McClain J.B., Hussey G.D., Hanekom W.A., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
23. De Cassan S., Pathan A., Sander C., Minassian A., Hill A.V., McShane H., Fletcher H. Investigating the induction of vaccine induced Th17 and regulatory T cells in healthy, BCG immunised adults vaccinated with a new tuberculosis vaccine, MVA85A. Clin Vaccine Immunol 2010, 17:1066-1073.
24. Griffiths K.L., Pathan A.A., Minassian A.M., Sander C.R., Beveridge N.E., Hill A.V., Fletcher H.A., McShane H. Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. PLoS ONE 2011, 6:e23463.
25. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., Keyser A., Moyo S., Brittain N., Lawrie A., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40:279-290.
26. Pamer E.G. Immune responses to Listeria monocytogenes. Nat Rev Immunol 2004, 4:812-823.
27. Jia Q., Bowen R., Sahakian J., Dillon B.J., Horwitz M.A. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge. Infect Immun 2013, 81:1550-1561.
28. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003, 9:729-735.
29. Yager E.J., Dean H.J., Fuller D.H. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev Vaccines 2009, 8:1205-1220.
30. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., Delaere P., Branellec D., Schwartz B., Scherman D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999, 96:4262-4267.
31. Chen J., Liu Q., Chen Q., Xiong C., Yao Y., Wang H., Wang H., Chen Z. Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice. Arch Virol 2013, Epub ahead of print. 10.1007/s00705-013-1878-1.
32. Wang Q., Jiang W., Chen Y., Liu P., Sheng C., Chen S., Zhang H., Pan C., Gao S., Huang W. In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses. J Virol 2013, 88(4):1924-1934.
33. Gopal R., Khader S.A. Vaccines against tuberculosis: moving forward with new concepts. Expert Rev Vaccines 2013, 12:829-831.
34. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., Mann P., Goosmann C., Bandermann S., Smith D., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
35. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204:1573-1584.
36. Sweeney K.A., Dao D.N., Goldberg M.F., Hsu T., Venkataswamy M.M., Henao-Tamayo M., Ordway D., Sellers R.S., Jain P., Chen B., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011, 17:1261-1268.
37. Perez E., Samper S., Bordas Y., Guilhot C., Gicquel B., Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001, 41:179-187.
38. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., Soto C.Y., Clark S.O., Hatch G.J., Aguilar D., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24:3408-3419.
39. Nambiar J.K., Pinto R., Aguilo J.I., Takatsu K., Martin C., Britton W.J., Triccas JA: 1. Protective immunity afforded by attenuated PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol 2012, 42:385-392.
40. Shen H., Harris G., Chen W., Sjostedt A., Ryden P., Conlan W. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS ONE 2010, 5:e91334.
41. Rockx-Brouwer D., Chong A., Wehrly T.D., Child R., Crane D.D., Celli J., Bosio C.M. Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS ONE 2012, 7:e37752.
42. Ota M.O., Odutola A.A., Owiafe P.K., Donkor S., Owolabi O.A., Brittain N.J., Williams N., Rowland-Jones S., Hill A.V., Adegbola R.A., et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011, 3(88):ra56.
43. Kaur T., Sobti R.C., Kaur S. Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice. Parasite Immunol 2011, 33:95-103.
44. Mazumder S., Maji M., Ali N. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Negl Trop Dis 2011, 5:e1429.
45. Chakravarty J., Kumar S., Trivedi S., Rai V.K., Singh A., Ashman J.A., Laughlin E.M., Coler R.N., Kahn S.J., Beckmann A.M., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011, 29:3531-3537.
46. Llanos-Cuentas A., Calderon W., Cruz M., Ashman J.A., Alves F.P., Coler R.N., Bogatzki L.Y., Bertholet S., Laughlin E.M., Kahn S.J., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010, 28:7427-7435.
47. Nascimento E., Fernandes D.F., Vieira E.P., Campos-Neto A., Ashman J.A., Alves F.P., Coler R.N., Bogatzki L.Y., Kahn S.J., Beckmann A.M., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010, 28:6581-6587.
48. Velez I.D., Gilchrist K., Martinez S., Ramirez-Pineda J.R., Ashman J.A., Alves F.P., Coler R.N., Bogatzki L.Y., Kahn S.J., Beckmann A.M., et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009, 28:329-337.
49. Ashtekar A.R., Katz J., Xu Q., Michalek S.M. A mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS. PLoS ONE 2012, 7:e05046.
50. Tifrea D.F., Pal S., Toussi D.N., Massari P., de la Maza L.M. Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge. Microbes Infect 2013, 15(13):920-927.
51. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., Schoolnik G.K., Cassidy J.P., Billeskov R., Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
52. Lin P.L., Dietrich J., Tan E., Abalos R.M., Burgos J., Bigbee C., Bigbee M., Milk L., Gideon H.P., Rodgers M., et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012, 122:303-314.